Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 12, 2006, Pages 840-844

  Mazur, Melissa ^a   Kurtzberg, Joanne ^a   Halperin, Edward ^a   Ciocci, Gilbert ^a   Szabolcs, Paul ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Hydroxyurea; Reduced intensity conditioning; Rituximab; Sickle cell disease; TBI; Thiotepa; Umbilical cord blood transplantation; Unrelated donor transplant

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFEROXAMINE MESYLATE; FLUDARABINE; HYDROXYUREA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; RITUXIMAB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ARTICLE; CASE REPORT; CORD BLOOD STEM CELL TRANSPLANTATION; ERYTHROCYTE TRANSFUSION; GALLSTONE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; IRON OVERLOAD; LIVER FIBROSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; STROKE; WEIGHT REDUCTION; WHOLE BODY RADIATION;

ANEMIA, SICKLE CELL; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FOLLOW-UP STUDIES; HUMANS; MALE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33845712655     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31802d3e53     Document Type: Article

References (20)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639.
2. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84:363.
3. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039.
4. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346.
5. de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91:125.
6. Walters MC. Stem cell therapy for sickle cell disease: transplantation and gene therapy. Hematology (Am Soc Hematol Educ Program). 2005;66.
7. Vermylen C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev. 2003;17:163.
8. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101:2137.
9. Kelly P, Kurtzberg J, Vichinsky E, et al. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr. 1997;130:695.
10. Kurtzberg J, Martin P, Chao N, et al. Unrelated placental blood in marrow transplantation. Stem Cells. 2000;18:153.
11. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918.
12. Adamkiewicz TV, Boyer MW, Bray R, et al. Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. J Pediatr Hematol Oncol. 2006;28:29.
13. Adamkiewicz TV, Mehta PS, Boyer MW, et al. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant. 2004;34:405.
14. Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005;35:171.
15. Jacobsohn DA, Duerst R, Tse W, et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of nonmalignant diseases in children. Lancet. 2004;364:156.
16. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519.
17. Shenoy S, Grossman WJ, Di Persio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35:345.
18. Schleuning M, Stoetzer O, Waterhouse C, et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol. 2002;30:7.
19. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant. 2004;33:613.
20. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915.